Clinical trial · Interventional
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual.
Summary
Brief summary (as posted)
1. Determine the feasibility of generation of autologous Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia in myeloid blast crisis (CML/BC) derived dendritic cell activated lymphocytes (DC/AL) in poor prognosis patients. 2. Determine the toxicity of autologous leukemia derived dendritic cell activated lymphocytes (DC/AL) in patients with AML or CML/BC. 3. Quantitate circulating immune effector cells in patients after infusion of DC/AL. 4. Record the efficacy of AML or CML/BC derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with AML or CML/BC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myelogenous Leukemia | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Chronic Myelogenous Leukemia | Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dendritic Cell Activated Lymphocyte | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dendritic Cell Activated Lymphocytes
- interventionNames
- Biological: Dendritic Cell Activated Lymphocyte
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion: * AML patients either after first relapse or at diagnosis a) with high-risk cytogenetics such as -7, -5, +8, chromosome 9 or 11 abnormality, or b) WBC \> 50,000, or c) age \> 60 years\*. * AML patients are eligible for cell collection if they have \> 1000 circulating blasts/mm at diagnosis. * CML patients in myeloid blast crisis with \> 1000 circulating blasts/mm. * Creatinine \<2, Bilirubin \<3. * Age \>18. Exclusion: * Factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure. * Concurrent or expected need for therapy with corticosteroids. * Positive antibody to human immunodeficiency virus I. * Acute promyelocytic Leukemia (FAB-M3). * History of overt cardiac failure, systemic autoimmune disease or expected need for steroid therapy. * Patients \>60 will be eligible for study but if found to have good prognosis cytogenetics (inversion (16) or t(8;21)) will subsequently be withdrawn from study and treated off protocol without infusion of autologous leukemia derived cells.
References
Publications (0)
Data not yet available